Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-816 + DPT-TAKEDA
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
TAK-816 + DPT-TAKEDA is a combination vaccine candidate developed by Takeda. TAK-816 is a Haemophilus influenzae type b (Hib) conjugate vaccine, licensed from Novartis (original product name: Vaxem Hib), containing 10µg of Poly-Ribosyl-Ribitol-Phosphate conjugated to 25µg CRM197, with aluminium phosphate as an adjuvant[2][3]. The DPT component refers to the diphtheria, pertussis (acellular), and tetanus vaccine formulation developed by Takeda. This combination was intended for pediatric immunization against invasive Hib disease as well as diphtheria, tetanus, and pertussis. However, there is no evidence that this specific combination reached advanced clinical development or approval; related programs were discontinued in favor of other priorities[1][2].
02
Targets
BCR (Immunoglobulin G B Cell Receptor)TCR-CRM197 (CRM197-specific T-cell receptor)γδ TCR (T-cell receptor)Diphtheria toxinPRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on TAK-816 + DPT-TAKEDA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-816 + DPT-TAKEDA.